Our vision is to make genetic medicines broadly accessible to address the unmet medical needs of patients.
Carmine Therapeutics is an EVX Ventures company that is headquartered in Cambridge, Massachusetts. We are pioneering powerful new genetic medicines that are based on red blood cell extracellular vesicles (RBCEVs).
Our proprietary Red Cell EV Gene Therapy (REGENT®) platform generates a pipeline of next-generation disease-modifying gene therapies for a broad spectrum of diseases.
Pioneering a New Class of Gene Therapies
By leveraging the unique properties of red blood cell extracellular vesicles (RBCEVs), we are developing next-generation non-viral gene therapies that overcome the current limitations of viral-based gene therapies such as immunogenicity, small transgene capacity, and manufacturing challenges.
Red Blood Cell Extracellular Vesicles (RBCEVs)
RBCEVs are physiologically produced by red blood cells. RBCs naturally lack genetic material, making RBCEVs biocompatible and non-immunogenic.
Large quantities of RBCEVs can be obtained from a single unit of blood, bypassing the need for culture expansion of cell source.
RBCEVs are highly amenable to manipulations such as nucleic acid loading and surface modification. This makes them ideally suited for gene therapy.
Published on 15 June 2018
in Nature Communications
Authors: Waqas Muhammad Usman, Tin Chanh Pham, Yuk Yan Kwok, Luyen Tien Vu, Victor Ma, Boya Peng, Yuen San Chan, Likun Wei, Siew Mei Chin, Ajijur Azad, Alex Bai-Liang He, Anskar Y. H. Leung, Mengsu Yang, Ng Shyh-Chang, William C. Cho, Jiahai Shi & Minh T. N. Le